Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314261 · ClinicalTrials.gov registry record · Phase 2
Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01314261 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 37 participants.
The verdict
NCT01314261, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, pharmacokinetics, and 4-week rapid virologic response (RVR) of 3 different doses of ABT-267 (also known as ombitasvir) in combination with pegylated interferon/ribavirin (pegIFN/RBV) compared with pegIFN/RBV alone (ABT-267 placebo) in treatment naïve, hepatitis C virus (HCV), genotype 1-infected participants.
Interventions
- DRUG Ribavirin (RBV)
- DRUG ABT-267
- DRUG Pegylated interferon (pegIFN)
- OTHER Placebo for ABT-267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01314261
The ClinicalTrials.gov registry entry for NCT01314261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin (RBV) is the first listed.
NCT01314261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01314261 about?
NCT01314261 is a clinical study titled "Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects". The purpose of this study was to assess the safety, pharmacokinetics, and 4-week rapid virologic response (RVR) of 3 different doses of ABT-267 (also known as ombitasvir) in combination with pegylated interferon/ribavirin (pegIFN/RBV) compared with pegIFN/RBV alone (ABT-267 placebo) in treatment naï...
What is the current status of trial NCT01314261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2011-03. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01314261?
The interventions under investigation include: Ribavirin (RBV) (DRUG), ABT-267 (DRUG), Pegylated interferon (pegIFN) (DRUG), Placebo for ABT-267 (OTHER).
Who is sponsoring clinical trial NCT01314261?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.